Welcome to our dedicated page for Waldencast plc news (Ticker: WALD), a resource for investors and traders seeking the latest updates and insights on Waldencast plc stock.
Waldencast plc (NASDAQ: WALD) is a global multi-brand beauty and wellness platform built around the Obagi Medical and Milk Makeup brands. Its news flow centers on segment performance, brand initiatives, and platform-level strategic decisions, providing investors and observers with regular insight into how the company executes its brand-led strategy.
Company updates frequently include quarterly and half-year financial results, furnished to the U.S. Securities and Exchange Commission on Form 6-K and summarized in detailed press releases. These communications break out net revenue, adjusted gross profit, and adjusted EBITDA for Waldencast as a whole and for the Obagi Medical and Milk Makeup segments, highlighting trends across channels and geographies as described by the company.
News related to Obagi Medical often covers product and portfolio developments, clinical data, and expansion into aesthetics. Examples include announcements about FDA approval of Obagi-branded hyaluronic acid injectable products, new clinical data on Obagi hyaluronic acid injectables and scalp serum at professional dermatology meetings, and the acquisition of Novaestiq Corp. and U.S. rights to the Saypha injectable line. These items illustrate how Waldencast presents Obagi Medical’s role at the intersection of skincare and medical aesthetics.
Updates about Milk Makeup focus on brand performance in prestige beauty and digital channels, including references to U.S. retail sales trends, expansion into retailers such as Ulta Beauty and Amazon Premium Beauty, and the impact of specific product launches as described in the company’s quarterly commentary.
At the corporate level, Waldencast’s news also addresses strategic reviews and financing actions, such as the announced review of strategic alternatives by the Board of Directors, the sale of the “Obagi” trademark in Japan, and new credit agreements. Readers of the WALD news page can expect a mix of earnings updates, brand-specific developments, clinical and regulatory milestones, and capital structure announcements directly sourced from company press releases and related SEC filings.
Waldencast Acquisition Corp. (NASDAQ: WALD) announced a new Credit Agreement on June 24, 2022, through its subsidiary, Waldencast Finco Limited. The agreement secures proceeds of up to approximately $1.02 billion, contingent on shareholder actions. Key components include a $175 million term loan and a revolving loan of up to $50 million. The financing will primarily be used for acquisitions of Milk Makeup and Obagi Skin Care, repayment of existing debts, and general corporate purposes, aimed at leveraging Waldencast's growth and operational strength.
Waldencast Acquisition Corp. (NASDAQ: WALD) announced its participation in the Cowen 6th Annual Future of the Consumer Conference on May 25, 2022. CEO Michel Brousset will engage in a fireside chat at 2:45 PM ET, with the event accessible via Waldencast's Investor Relations page. The company aims to develop a leading beauty and wellness platform through strategic acquisitions, including its proposed combination with Obagi Global Holdings and Milk Makeup. Waldencast focuses on conscious brands aligning with social responsibility and sustainability.
Waldencast Acquisition Corp. (NASDAQ: WALD) hosted an Analyst Day on April 27, 2022, highlighting its mission to create a premier beauty and wellness platform by merging with Obagi Global Holdings and Milk Makeup. The company focuses on brands that fulfill consumer demands for social responsibility and sustainability. Waldencast filed a registration statement with the SEC in February 2022, outlining the proposed transactions and relevant financial details. Investors are encouraged to review the proxy statement for important information regarding the mergers and associated risks.
Milk Makeup has appointed Nilofer Vahora as its new Chief Marketing Officer (CMO). Vahora brings 14 years of experience from her previous role at Shiseido. This strategic hire follows Waldencast Acquisition Corp.'s $1.2 billion business combination with Milk Makeup and Obagi, aimed at creating a global beauty platform. Both the CEO and co-founder of Milk Makeup expressed confidence in Vahora's ability to drive growth while staying true to the brand's values of clean, vegan, and cruelty-free products.
Waldencast Acquisition Corp. (NASDAQ: WALD) has announced that CEO Michel Brousset will participate in investor meetings and a fireside chat at the D.A. Davidson 5th Annual Consumer Growth Conference on March 10, 2022. Waldencast will also join Evercore ISI CPG Growth Day on March 22, 2022. The discussions aim to promote Waldencast's vision of building a best-in-class beauty and wellness operating platform through partnerships with purpose-driven brands like Obagi and Milk Makeup. Key financial documents regarding these proposed transactions have been filed with the SEC.
Waldencast Acquisition Corp. (NASDAQ: WALD) has announced a definitive business combination with Obagi and Milk Makeup, valued at approximately $1.2 billion. The merger aims to establish a global beauty platform focused on high-growth, purpose-driven brands. The transaction will be funded through a combination of IPO cash, Forward Purchase Agreements, and rollover equity. Waldencast's leadership will include industry veterans, with the goal of driving growth and shareholder value. The merger is expected to close in the first half of 2022, pending shareholder approval.
Waldencast Acquisition Corp. (NASDAQ: WALD) received a notice from Nasdaq on May 28, 2021, for failing to timely file its Quarterly Report on Form 10-Q for the quarter ending March 31, 2021. This non-compliance with Nasdaq Listing Rule 5250(c)(1) does not immediately affect its securities listing, which will continue to trade on Nasdaq. WALD has 60 days to file the Form 10-Q or submit a compliance plan. If accepted, Nasdaq may grant up to 180 days for compliance, until November 22, 2021. The Company is also evaluating the accounting treatment of its warrants under recent SEC guidance.
Summary not available.